This clinical trial is focused on studying the long-term safety of a medication called brigimadlin in patients with solid tumors. Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. The study involves patients who have already participated in a previous trial with brigimadlin. Brigimadlin is taken as a film-coated tablet and is designed to be used as a monotherapy, meaning it is used alone without combining it with other treatments.

The purpose of this study is to evaluate how safe and tolerable brigimadlin is over a long period. Participants will continue taking brigimadlin and will be monitored for any side effects that may occur during the treatment. The study will look at how often these side effects happen, how severe they are, and how they relate to the treatment. This information will help understand the long-term effects of using brigimadlin in treating solid tumors.

Participants in this study will take brigimadlin orally, which means they will swallow the tablets. The study will last for a maximum of 60 days, during which the participants will have regular check-ups to monitor their health and any side effects they might experience. The study aims to ensure that brigimadlin is safe for long-term use in patients with solid tumors who have already been treated with this medication in a previous trial.